Novel quinoxaline-di-N-oxide derivatives of the general formula ##STR1## in which R1 is hydrogen or straight-chain or branched-chain alkyl having 1 to 4 carbon atoms,
R2 and R3 independently of one another are each straight-chain or branched-chain alkyl having 1 to 4 carbon atoms, or together with the N atom they form a heterocyclic ring which is unsubstituted or is substituted by alkyl having 1 to 4 carbon atoms, and which has 4 to 5 ring carbon atoms and optionally an oxygen atom as further hetero atom,
R4 is hydrogen, methoxy, methylthio, hydroxyl, fluorine, chlorine, bromine or cyano,
A is alkylene having 1 to 4 carbon atoms, with the proviso that if R4 has a meaning other than cyano, A is 1,2-ethylene, and R1 is hydrogen,
including the acid addition salts thereof; processes for producing them; compositions containing these compounds; and the use thereof. The novel active substances serve to combat pathogenic microorganisms in the field of veterinary medicine. They are effective in the case of diseases of the respiratory tract in poultry, and infections of the intestinal tract and of the urogenital system in domestic animals and productive livestock. They are in addition suitable as a feed additive for promoting the growth of animals. Depending on the type of application, the novel active substances may be administered perorally or via the abomasum or directly by injection, the active substances being applied on their own or in combination with customary inert carriers, either in the solid form or in the liquid form.
|
7. A quinoxaline-di-N-oxide of the formula ##STR40##
3. A quinoxaline-di-N-oxide salt of the formula ##STR36##
8. A quinoxaline-di-N-oxide salt of the formula ##STR41##
4. A quinoxaline-di-N-oxide salt of the formula ##STR37##
5. A quinoxaline-di-N-oxide salt of the formula ##STR38##
6. A quinoxaline-di-N-oxide salt of the formula ##STR39##
2. A quinoxaline-di-N-oxide derivative of the general formula ib ##STR35## in which R1 is hydrogen or C1 -C4 -alkyl, and R2 and R3 independently of one another are each C1 -C4 -alkyl, or together with the N atom they form a heterocyclic ring which is unsubstituted or is substituted by C1 -C4 -alkyl and which has 4 to 5 ring carbon atoms and optionally an oxygen atom as further hetero atom, including the acid addition salts thereof.
1. A quinoxaline-di-N-oxide derivative of the general formula I ##STR34## in which R1 is hydrogen or straight-chain or branched-chain alkyl having 1 to 4 carbon atoms,
R2 and R3 independently of one another are each straight-chain or branched-chain alkyl having 1 to 4 carbon atoms, or together with the N atom they form a heterocyclic ring which is unsubstituted or is substituted by alkyl having 1 to 4 carbon atoms, and which has 4 to 5 ring carbon atoms and optionally an oxygen atom as further hetero atom, R4 is hydrogen, methoxy, methylthio, hydroxyl, fluorine, chlorine, bromine or cyano, and A is alkylene having 1 to 4 carbon atoms, with the proviso that if R4 has a meaning other than cyano, A is 1,2-ethylene, and R1 is hydrogen,
including the acid addition salts thereof. 9. A composition for combating harmful microorganisms or for promoting the growth of domestic animals, which contains as active substance an effective amount of at least one compound of the formula I, or one of its addition salts, according to
10. A method for promoting the growth of animals and of productive livestock which comprises administering to said animals and said productive livestock a growth promoting amount of a compound of the formula I or an acid addition salt thereof according to
|
The present invention relates to novel quinoxaline-di-N-oxide derivatives, to processes for producing them, to compositions containing the novel compounds, and to the use thereof for combating pathogenic microorganisms, and also as a feed additive for domestic animals and for productive livestock.
The novel quinoxaline-di-N-oxide derivatives correspond to the general formula I ##STR2## in which R1 is hydrogen or straight-chain or branched-cain alkyl having 1 to 4 carbon atoms,
R2 and R3 independently of one another are each straight-chain or branched-chain alkyl having 1 to 4 carbon atoms, or together with the N atom they form a heterocyclic ring which is unsubstituted or is substituted by alkyl having 1 to 4 carbon atoms, and which has 4 to 5 ring carbon atoms and optionally an oxygen atom as further hetero atom,
R4 is hydrogen, methoxy, methylthio, hydroxyl, fluorine, chlorine, bromine or cyano,
A is alkylene having 1 to 4 carbon atoms, with the proviso that if R4 has a meaning other than cyano, A is 1,2-ethylene, and R1 is hydrogen,
and include the acid addition salts thereof.
By alkyl are meant methyl, ethyl and the isomers of the propyl group and of the butyl group.
To be mentioned as examples of the acid anions of the acid addition salts are: acetate, citrate, maleate, lactate, furmarate, pamoate, tosylate, bromide and preferably chloride, and also salts with ion exchangers, for example Amberlist 15.
Substances which are structurally similar to the compounds of the formula I according to the invention are already known from the German Offenlegungsschriften Nos. 1,670,935 and 1,620,114, and from the British Patent Specification No. 1,223,720. For combating pathogenic microorganisms, the compounds of the formulae I and Ia according to the invention are distinctly superior to the known compounds, and compared with these known compounds they are characterised by a more pronounced therapeutic activity and also by low toxicity. Furthermore, they are in an advantageous manner readily soluble both in water and in organic solvents.
The compounds of the formula I according to the invention have a good microbicidal action, and are suitable for combating pathogenic microorganisms in the field of veterinary medicine. They are distinguished by a good action against diseases of the respiratory tract caused by E. coli in poultry. The novel compounds of the invention are in addition suitable for controlling infections of the intestinal tract, for example diarrhoea in pigs, and also infections of the urogenital system.
The novel compounds also have good properties for promoting the growth of domestic animals, and of productive livestock, such as pigs, poultry and ruminants.
Compounds which are distinguished by high effectiveness with regard to their properties as substances which promote animal growth and which at the same time have low toxicity are in particular the compounds of the formula Ib ##STR3## in which R1 is hydrogen or C1 -C4 -alkyl, and R2 and R3 independently of one another are each C1 -C4 -alkyl, or together with the N atom they form a heterocyclic ring which is unsubstituted or is substituted by C1 -C4 -alkyl, and which has 4 to 5 ring carbon atoms and optionally an oxygen atom as further hetero atom, and the acid addition salts of these compounds.
Among the compounds of the formula Ib, the following are to be mentioned as compounds having particularly favourable toxicity values in the case of pigs and poultry:
______________________________________ |
Compound Table 1 |
##STR4## |
or |
##STR5## |
Comp. No. |
1 2 3 4 5 |
______________________________________ |
R2 : R3 : |
##STR6## CH3 CH3 |
##STR7## |
##STR8## |
C2 H5 C2 |
H5 |
X: Cl Cl Cl Cl -- |
______________________________________ |
A further compound likewise having a good action in promoting growth and having low toxicity is the following: ##STR9##
Depending on the intended use, the active substances according to the invention may be administered to the animals perorally or via the abomasum or directly by injection into the animals, in single doses or in repeated doses, the active substances being applied, on their own or in combination with inert carriers and/or diluents, in the form of solutions, emulsions, suspensions, powders, tablets, boluses and capsules. The active substances or mixtures containing them can also be added to the feed or to the drinking water, or they can be contained in so-called feed premixes.
The good therapeutic activity of the compounds of the formulae I and Ia was able to be verified both in vitro and, in particular, on the animal, after either oral or subcutaneous application, in the case of acute bacterial infections. The sphere of action of the said compounds embraces both gram-positive and gram-negative bacteria.
The compounds of the formula I can be produced, using known methods, from 1,4-dioxido-3-methyl-quinoxaline-(2)-carboxylic acid amides [see Organic Reactions, Vol. I (1942) 312] in the following manner: ##STR10## or their acid addition salts: ##STR11## and the salts of the formula Ia can be converted into the free compounds of the formula I as follows: ##STR12##
In the given formulae, the radicals R1 to R4 have the meanings initially given under the formula I, and X is the anion of an inorganic or organic acid.
The reaction is carried out in organic solvents inert to the reactants, for example formamide, N-methylformamide, dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dioxane, toluene, propionitrile, butyronitrile, benzonitrile, methyl cellosolve or preferably acetonitrile.
The reaction is performed at temperatures of 20° to 150°C, preferably 40° to 80°C
Some of the starting materials of the formula II used to produce the compounds of the formula I according to the invention have already been described (see German Offenlegungsschriften Nos. 1,670,935 and 211 710, British Patent Specification No. 1,308,370, and Swiss Patent Application No. 7718/77). When R4 in formula II is fluorine, the corresponding compound can be produced by a process given in the aforementioned descriptions. In the case where R4 is bromine, R1 is hydrogen and A is ethylene (see formula II'), the following new production process is used: ##STR13##
When R4 is chlorine, the corresponding compound of the formula II" (Cl in place of Br in formula II'), which has already been mentioned in German Offenlegungsschrift No. 2,111,710, can be produced likewise using the above-described process by reaction of 2-[oxazolinyl(2')]-3-methyl-quinoxaline-1,4-di-N-oxide (German Offenlegungsschrift No. 2,111,710, Example 21) with concentrated aqueous hydrochloric acid.
Also known are the secondary amines, and their acid addition salts, used as starting materials of the formula III and IIIa, of which are to be mentioned as examples: dimethylamine, diethylamine, di-n-propylamine, di-isopropylamine, di-n-butylamine, pyrrolidine, piperidine and morpholine, and also acid addition salts thereof.
The formaldehyde used in the process for producing the compounds of the formulae I and Ia can be employed either in the form of an aqueous solution or in the form of solid agents splitting off formaldehyde, for example paraformaldehyde.
(a) 49 g (0.2 mol) of 2-[oxazolinyl(2')]-3-methyl-quinoxaline-1.4-di-N-oxide is added to 200 ml of 48% aqueous hydrobromic acid, and the mixture is subsequently stirred for one further hour at room temperature. 500 g of ice is added to this mixture, and a colourless crystalline product precipitates; it is then filtered off, and dried at room temperature over phosphorus pentoxide. The yield is 63.1 g (96.7%) of 1,4-dioxido-3-methyl-quinoxaline(2)-N-(2'-bromoethyl)-carboxylic acid amide, which melts at 165°C with decomposition.
(b) 24.5 g (0.075 mol) of 1.4-dioxido-3-methyl-quinoxaline (2)-N-(2'-bromoethyl)-carboxylic acid amide, 2.3 g of paraformaldehyde and 6 g of dimethylamine hydrochloride are placed together with 180 ml of acetonitrile into the reaction vessel, and the whole is heated in an oil bath at 100°C The suspension gradually turns into a clear solution, which is held, with stirring, for a further 20 hours at the same temperature. The solution is subsequently cooled to 10°C, and a product crystallises out. The mixture is then heated to 60°C, and afterwards filtered. The yield is 14.6 g (46.5%) of 1.4-dioxido-3-(2'-dimethylaminoethyl)-quinoxaline(2)-N-(2"-bromoethyl)carb oxylic acid amide hydrochloride, which melts at 164°-166°C with decomposition.
(a) 2.2 g of n-butylamine is added dropwise, during 10 minutes, to a suspension of 4.4 g (0.03 mol) of N-2-fluoroethylacetoacetic acid amide and 4 g of benzofuroxane in 30 ml of methanol, in the course of which the temperature rises to 35°C, and for a short time there is formed a clear dark-coloured solution. Stirring is continued at the same temperature in the water bath; the temperature is lowered after 10 hours to 20°C; the crystalline product which has precipitated is filtered off with suction, and is washed with a small amount of cold methanol; the product is recrystallised from methanol to yield 6 g (75.9%) of pure crystalline 1.4-dioxido-3-methyl-quinoxaline-(2)-N-(2'-fluoroethyl)-carboxylic acid amide, which melts at 200°-202°C
(b) 52.4 g (0.2 mol) of 1.4-dioxido-3-methyl-quinoxaline (2)-N-(2'-fluoroethyl)-carboxylic acid amide, 6 g of paraformaldehyde and 16 g of dimethylamine hydrochloride in 500 ml of acetonitrile are heated in an oil-bath at 100°C The suspension gradually becomes a clear solution, which is maintained at the same temperature, with stirring, for a further 20 hours, with a crystalline product slowly commencing to crystallise out after 10 hours. This is filtered off from the warm mixture, and is recrystallised from ethanol to thus obtain 45.6 g (63.7%) of 1.4-dioxido-3-(2'-dimethylaminoethyl)-quinoxaline(2)-N-(2'-fluoroethyl)-ca rboxylic acid amide hydrochloride, which melts at 182°-184° C. with decomposition.
(c) 3.6 g (0.01 mol) of 1.4-dioxido-3-(2'-dimethylaminoethyl)-quinoxaline(2)-N-(2"-fluoroethyl)-ca rboxylic acid amide hydrochloride is dissolved in a mixture of 30 ml of water and 30 ml of methylene chloride; to this mixture is then added, with stirring, 10 ml of 1 N sodium hydroxide solution, and the methylene chloride phase is immediately separated. There is obtained from the solution, dried over sodium sulfate, 2.7 g (84.4%) of pure crystalline 1.4-dioxido-3-(2'-dimethylaminoethyl)-quinoxaline(2)-N-(2"-fluoroethyl)-ca rboxylic acid amide, m.p. 166°-167°C
27.2 g (0.1 mol) of 1,4-dioxido-3-methyl-quinoxaline (2)-N-(2'-cyanoethyl)-carboxylic acid amide is suspended with 20 g (0.2 mol) of 30% aqueous formaldehyde solution and 14.6 g (0.2 mol) of diethylamine in 250 ml of acetonitrile. Stirring is subsequently maintained for 16 hours at 40°C, and the clear solution formed is concentrated by evaporation. After the addition of methanol to the oily residue, there is precipitated from the clear dark-brown-coloured solution 23.4 g (65.5%) of 1,4-dioxido-3-(2'-diethylaminoethyl)-quinoxaline(2)-N-(2'-cyanoethyl)-carb oxylic acid amide in the form of deep-yellow crystals, which melt at 159°-160°C with decomposition.
13.6 g (0.05 mol) of 1,4-dioxido-3-methyl-quinoxaline(2)-N-(2'-cyanoethyl)-carboxylic acid amide is suspended with 10 g (0.1 mol) of 30% aqueous formaldehyde solution and 8.1 g (0.1 mol) of dimethylamine hydrochloride in 200 ml of acetonitrile. The suspension is subsequently stirred under reflux for 24 hours, and 13.6 g (74.3%) of yellowish-white crystals of 1.4-dioxido-3-(2'-dimethylaminoethyl)-quinoxaline(2)-(2'-cyanoethyl)-carbo xylic acid amide hydrochloride is then filtered off hot; the crystals melt at 211°-213°C with decomposition.
17.8 g (0.05 mol) of 1,4-dioxido-3-(2'-diethylaminoethyl)-quinoxaline(2)-N-(2'-cyanoethyl)-carb oxylic acid amide is suspended in 50 ml of water, and then dissolved, with cooling, at 20°C in 50 ml of 1 N hydrochloric acid. The clear light-coloured solution is evaporated to dryness; residual moisture is removed by drying over phosphorus pentoxide. The highly viscous residue is recrystallised from isopropanol/acetone to yield 12.5 g (63.6%) of 1,4-dioxido-3-(2'-diethylaminoethyl)-quinoxaline(2)-n-(2'-cyanoethyl)-carb oxylic acid amide hydrochloride in the form of yellowish-white crystals, which melt at 180°-181°C
18.2 g (0.05 mol) of 1,4-dioxido-3-(2'-dimethylaminoethyl)-quinoxaline(2)-(2'-cyanoethyl)-carbo xylic acid amide hydrochloride is dissolved in 100 ml of water. There is then added, at a temperature of 20°C, 50 ml of 1 N sodium hydroxide solution, and the solution is extracted with methylene chloride. From the methylene chloride phase, dried over sodium sulfate, is obtained 15.6 g (95%) of 1,4-dioxido-3-(2'-dimethylaminoethyl)-quinoxaline(2)-(2'-cyanoethyl)-carbo xylic acid amide, which melts at 161°C with decomposition.
The following compounds were produced or are producible by processes analogous to those described in the Examples:
__________________________________________________________________________ |
Compound Table 2 |
##STR20## |
##STR21## |
No. A R1 |
R2 |
R3 |
R4 |
X m.p. in °C. |
__________________________________________________________________________ |
1 CH2 |
H CH3 |
CH3 |
CN Cl 179-181 |
2 CH2 |
H CH3 CH2 |
CH3 CH2 |
CN -- 156-157 |
3 CH2 |
H CH3 CH2 |
CH3 CH2 |
CN Cl |
4 CH2CH2 |
H CH3 (CH2)2 |
CH3 (CH2)2 |
CN -- 128-130 |
5 CH2CH2 |
H CH3 (CH2)3 |
CH3 (CH2)3 |
CN -- 130-132 |
6 CH2CH2 |
H |
##STR22## CN -- 160-161 |
7 CH2CH2 |
H |
##STR23## CN -- 160-161 |
##STR24## |
H CH3 |
CH3 |
CN Cl |
9 |
##STR25## |
H CH3 CH2 |
CH3 CH2 |
CN -- 136-138 |
10 |
##STR26## |
H CH3 CH2 |
CH3 CH2 |
CN Cl |
11 CH2 |
H CH3 |
CH3 |
CN Br 158-160 |
12 CH2CH2 |
H CH3 |
CH3 |
CN -- 158-160 |
13 CH2CH2 |
H CH3 |
CH3 |
CN Br 202(decomp.) |
14 CH2CH2 |
H |
##STR27## CN Cl 187-189 |
15 CH2CH2 |
H CH3 |
CH3 |
CN Cl 211-213 |
16 CH2CH2 |
H CH3 |
CH3 |
CN Amber- |
> 300 |
list 15 |
17 CH2CH2 |
H CH3CH2 |
CH3CH2 |
CN -- 158-159 |
18 CH2CH2 |
H CH3CH2 |
CH3CH2 |
CN Cl 180-181 |
19 CH2CH2 |
H CH3CH2 |
CH3CH 2 |
CN Amber- |
> 300 |
list 15 |
20 CH2CH2 |
H |
##STR28## CN Cl 190-192 |
21 CH2CH2 |
H |
##STR29## CN Cl 192 |
22 CH2CH2 |
H CH3 |
CH3 |
OH Cl 159-160(decomp) |
23 CH2CH2 |
H CH3 |
CH3 |
SCH3 |
Cl 185-186 |
24 CH2CH2 |
H CH3 |
CH3 |
SCH3 |
-- 138-139 |
25 CH2CH2 |
H CH3 |
CH3 |
OCH3 |
Cl 196-197 |
26 CH2CH2 |
H CH3 |
CH3 |
OCH3 |
-- 150-152 |
27 CH2CH2 |
H CH3 |
CH3 |
Br Cl 164-166 |
28 CH2CH2 |
H CH3 |
CH3 |
Cl Cl 194-196(decomp) |
29 CH2CH2 |
H CH3 |
CH3 |
Cl -- 139-140 |
30 CH2CH2 |
H |
##STR30## F Cl 182-183(decomp) |
31 CH2CH2 |
H |
##STR31## F -- 174-175 |
32 CH2CH2 |
H CH3 |
CH3 |
H Cl 183-185(decomp) |
33 CH2CH2 |
H CH3 |
CH3 |
H -- 153-155 |
34 CH2CH2 |
H |
##STR32## H Cl 188-190(decomp) |
35 CH2CH2 |
H |
##STR33## H -- 185-186 |
36 CH2CH2 |
H CH3 |
CH3 |
F Cl 182 |
37 CH2CH2 |
H CH3 |
CH3 |
F -- 166-167 |
__________________________________________________________________________ |
For producing final feed containing as active substance a compound of the formula I or an acid addition salt thereof (formula Ia) at a concentration of (a) 25 ppm, (b) 50 ppm, (c) 200 ppm and (d) 400 ppm, there are prepared the following feed premixes:
______________________________________ |
(a) 0.15 part by weight of one of the compounds according |
to formula I or Ia, |
49.85 parts by weight of bolus alba, |
150.0 parts by weight of standard feed for poultry, |
pigs or ruminants, |
(b) 0.30 part by weight of one of the compounds according |
to formula I or Ia, |
44.70 parts by weight of bolus alba, |
5.0 parts by weight of silicic acid, |
150.0 parts by weight of standard feed for poultry, |
pigs or ruminants, |
(c) 1.2 parts by weight of one of the compounds according |
to formula I or Ia, |
43.8 parts by weight of bolus alba, |
5.0 parts by weight of silicic acid, |
150.0 parts by weight of standard feed for poultry, |
pigs or ruminants, |
(d) 2.4 parts by weight of one of the compounds according |
to formula I or Ia, |
47.6 parts by weight of bolus alba, |
150.0 parts by weight of standard feed for poultry, |
pigs or ruminants. |
______________________________________ |
The active substances are either mixed directly in with the carrier materials, or absorbed, after being dissolved in a suitable solvent, onto the carrier materials. The mixture is subsequently ground to the desired particle size of, for example, 5-10 microns. These feed premixes are mixed with 5800 parts by weight of standard feed, or are processed to give 6000 parts by weight of finished drinking liquid.
Furthermore, the final feed mixtures can be pelletised (feed pellets).
The active substances of the formula I or Ia according to the invention are added to the feed or to the drinking liquids for the animals, either directly or in the form of a premix, in amounts of 1 to 500 ppm, relative to the total amount of feed or drinking liquid.
Suitable premixes consist for example of a mixture of the active substance for instance with kaolin, limestone, aluminium oxide, ground shells, bolus alba, aerosol, starch or second flour, such as wheat second flour. A feed mixture is produced by thoroughly mixing the necessary amount of premix with the appropriate amount of a commercial standard feed.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
3557109, | |||
4092415, | Jan 20 1976 | Ciba-Geigy Corporation | Microorganism combatting quinoxaline-di-N-oxide carboxamides |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Dec 10 1979 | Ciba-Geigy Corporation | (assignment on the face of the patent) | / | |||
Oct 07 1980 | Ciba-Geigy AG | CIBA-GEIGY CORPORATION, A CORP OF N Y | ASSIGNMENT OF ASSIGNORS INTEREST | 003807 | /0374 |
Date | Maintenance Fee Events |
Date | Maintenance Schedule |
Mar 03 1984 | 4 years fee payment window open |
Sep 03 1984 | 6 months grace period start (w surcharge) |
Mar 03 1985 | patent expiry (for year 4) |
Mar 03 1987 | 2 years to revive unintentionally abandoned end. (for year 4) |
Mar 03 1988 | 8 years fee payment window open |
Sep 03 1988 | 6 months grace period start (w surcharge) |
Mar 03 1989 | patent expiry (for year 8) |
Mar 03 1991 | 2 years to revive unintentionally abandoned end. (for year 8) |
Mar 03 1992 | 12 years fee payment window open |
Sep 03 1992 | 6 months grace period start (w surcharge) |
Mar 03 1993 | patent expiry (for year 12) |
Mar 03 1995 | 2 years to revive unintentionally abandoned end. (for year 12) |